Vo l . 2 , N o . 2 , D e c e m b e r 2 0 0 8 2 r e v i e w s i n p a i n The National Institutes of Health (NIH) sets the agenda for medical research in the USA. Over the past few years, the NIH has organised several meetings to examine the nature of the urogenital pain syndromes and to move the program for UGP research forward. They have recognised the importance of having appropriate 'end-organ' investigations to exclude other disease process, and have taken on board that the urogenital pain syndromes require both an interdisciplinary (collaboration between specialities, e.g., urology, gynaecology, pain medicine) and multidisciplinary (collaboration between disciplines, e.g. psychology, medical, physiotherapy) approach. The above 2 day meeting, 'Defining the Urologic Chronic Pelvic Pain Syndromes -A New Beginning', aimed to consolidate the above stance and brought together expert opinion from clinicians, clinical scientists and basic scientists to discuss the future research in this field. There was to be a heavy emphasis on the systemic nature of the disease process and the cognitive, behavioural, emotional and sexual associations of the pain syndromes as well as the range of abnormal sensory perceptions and functional responses frequently seen. As well as those speakers regarded as having a significant input into the field, an expert panel, whose purpose it is to advise the NIH on future research, was convened to correlate the presentations and discussions. Finally, the meeting was open to those with a vested interest in the field such, as the patient support groups.
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It was in recognition of the multidisciplinary approach to pain management adopted in the UK that I was invited to open the meeting with a presentation on the classification and hence the clinical approach to urogenital pain management. It is important to appreciate that classification consists of three parts. Firstly we need to define the disease that we are interested in (phenotype), secondly we need to give it a name (terminology) and finally place it in a hierarchy of other conditions (Taxonomy). When it comes down to urogenital pain classification, specialists and patient support groups argue over all three parts! In my opinion, the European Association for Urology guidelines currently provide the most robust classification system, both for clinical practice and research 1 . Much of the argument has been around terminology, which we argue should be meaningful and not spurious leading to inappropriate treatment 2, 3 . It was also in recognition of the European perspective that Paul Abrams, UK [International Continence Society] and Jorgen Nordling, Denmark [ESSIC -European Society for the Study of Interstitial Cystitis], both 'converted' urologists, and Mauro Cervigni, an Italian urogynaecologist, were invited. The essential thrust of the European approach has been to move away from considering the problem as being an'end-organ' process, such as due to infection, inflammation or recurrent trauma associated with pain. The guidelines that the European's have published, supported by international editorials have emphasised the importance of ruling out a local pathology by an appropriate specialist as early as possible and then moving on to treating the urogential pain has being primarily a neurological condition with associated cognitive, behavioural, emotional, sexual and social consequences 4,5,6 . The latest version of the European guidelines published by the European Association of Urology emphasised the multidisciplinary approach should be adopted. This approach is also inline the work of Curtis Nickel (urology) and Dean Tripp (psychology), both Canadians, in research that has demonstrated the importance of psychological factors in the phenotype, the management and prognosis of the condition. Their research has demonstrated that the factors considered important for the management of chronic back pain are quite similar to those for urogenital pain, with catastrophising, poor locus of control, and low mood being poor prognostic factors 7 .
As a result of the above changes in approach to management and previous fact finding meetings the National Institutes of Health set up the MAPP research Network. MAPP being the Multi-disciplinary Approach to the Study of Chronic Pelvic Pain 8 . This research is still ongoing.
The MAPP program has been devised not only to collect information on the cognitive behavioural associations with Chronic Pelvic Pain but also to investigate the other associations. To understand this further, at the NIH meeting this last June, Jack Warren (Medicine, USA) presented his research that indicates that in patients where the pain is perceived to be originating from the bladder they actually perceive the pain in a significant number of varying sites. It is frequently super pubic, in 83% of cases; however, in 36% of cases it was perceived as urethral, 23% of cases genital and in non genital urinary sites in 29%. The cases with urethral or genital pain did not differ in terms of other factors looked at, such as demographics, sexual history and other symptoms. In a presentation by J. Quentin Clemens (Urology, USA) he emphasised that urological disease could be due to a disorder of the afferent nervous system, the efferent nervous system or structural are now much more clearly understood, with a move away from considering the 'end-organ' as being responsible towards a central neuroplasticity theory and as a consequence both a multidisciplinary and interdisciplinary approach to management. r e v i e w s i n p a i n and that much more work needs to be undertaken on the first of these mechanisms. These mechanisms often overlap (Fig1) and may be the reason as to why we see such variable clinical pictures. Michael Pezzone (Gastroenterology, USA) presented work that emphasised the importance of cross talk within the nervous system 9 . It is now well established that irritation within the bladder, e.g. due to an infection, may produce a central sensitisation process with increased perception of afferent activity and abnormal efferent activity not only in the bladder but also associated with the other pelvic organs. This is the probable cause of the high incidence of bowel symptoms and dysmenorrhoea in patients with the Bladder Pain Syndrome (previously known as Interstitial Cystitis). Dedra Buchwald (Epidemiology, USA) presented the clinical research to support the basic science. As a result of a systematic review of the Bladder Pain Syndrome (Interstitial Cystitis/ Painful Bladder Syndrome) literature, 41 publications meeting their criteria were found. These demonstrated a significant clinical overlap between Bladder Pain Syndrome and irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome with figures varying from 10% up to 70% depending upon the combinations looked at. Further evidence for UGP having a central nervous system component and that it is often associated with other systemic symptoms came from presentations by: Daniel J Clauw (Fibromyalgia, Rheumatologist, USA), Emeran A Myer (Chronic Fatigue Syndrome, Psychiatry, USA) and Robert Moldwin (Vulvar Pain Syndrome, Urologist, USA).
Having appreciated the link between the various syndromes, the question as to whether or not the UGP syndromes are a part of a systemic disease process or coincidental findings was taken up by a number of experts. They presented research evidence to suggest that there are significant links between the neuroendocrine and neuroimmune systems that could explain the associations. In particular Tony Buffington (Veterinary Science, USA) presented his research on the effect of stress in cats and how this can produce symptoms and signs that are in parallel to the human Bladder Pain Syndrome / Interstitial Cystitis 10 . Professor Buffington's cats were all 'patients'cats with owners who brought them for treatment! Interestingly, within a double blind study of his 'patients' cats, by changing the behaviour of their owners Professor Buffington was able to change the symptoms of 'interstital cystitis' and the cats were more alert and less lethargic with a more normal urinination pattern. Systematic studies that he has carried out demonstrated the importance of the neuroendocrine system in generating the pathology. Anthony J Schaeffer (Urology, USA) presented an overview of proposed mechanisms for Chronic Pelvic Pain, including his research on the immune system 11 . J Curtis Nickel, summarised his overview of Chronic Urogenital Pain. Essentially, it is thought that there are certain genotypes that may predispose to chronic pain and these combined with a range of developmental and environmental factors may result in an individual susceptible to developing a chronic urogenital pain syndrome. These predisposing factors Curtis Nickel refers to as induction factors (Fig 2) . As we will see below, the predisposing factors may effect not only the onset of the pain, but its progression and hence the name induction is preferred. In most patients acute painful events resolve over a short period of time. In the susceptible patient with appropriate induction factors the pain persists due to central nervous system changes. The acute painful event that precedes the pain syndrome is known as the initiating event. The initiating event may or may not be associated with a short period of inflammation, with or without tissue damage; it may be associated with a muscle spasm or an extreme psychologically stressful situation.
Change from an acute pain mechanism to a chronic pain syndrome is maintained by changes in the central nervous system. Again these chronic pain central changes may resolve after a period of days or weeks but under certain circumstances become maintained due to the function of the neurological system and its interaction of other systems.
Further changes in the nervous system, affecting both the afferent and the efferent nervous system, will progress the condition from being a well localised End-organ Pain Syndrome into a Regional Chronic Pain Syndrome. The Regional Chronic Pain Syndromes have abnormalities of the efferent function as well as afferent perception. Finally, further progression of the condition may result in a Systemic Urogenital Pain Syndrome with widespread symptoms and signs which parallel the conditions of fibromyalgia and chronic fatigue syndrome. The MAPP research programme has been devised to investigate these links and thus removes the emphasise from the end organ towards the pelvis as a whole, as well as the neurological system in its entirety including the neuroendocrine, neuroimmune, psychological, behavioural, sexual and social associations. Treatment and management need to be aimed at all of these factors.
Urinary sensory symptoms may be due to: 1) Structural disorders such as related to pelvic prolapse, stress incontinence, diminished bladder capacity or bladder outflow obstruction.
2) Afferent disorders with abnormal processing within the whole of the neuroaxis such as found in The Bladder Pain Syndrome, Prostate Pain Syndrome, Testicular Pain Syndrome and Over Active Bladder Dry.
3). Efferent disorders such as associated with Over Active Bladder Wet, Detrusor Sphincter Dyssynergy and Detrusor Sphincter Overactivity.
Separating the components out may be difficult as the disorders may overlap and indeed may have similar central nervous system mechanisms in certain cases. 
